Regeneron Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:REGN
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 45 out of 928
Universe
Global Universe 3001 out of 16421
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Regeneron Pharmaceuticals, Inc. |
17.3
Low
|
45 out of 928 |
Vertex Pharmaceuticals, Inc. |
20.3
Medium
|
89 out of 928 |
Bristol Myers Squibb Co. |
22.3
Medium
|
126 out of 928 |
Amgen, Inc. |
23.8
Medium
|
166 out of 928 |
CSL Ltd. |
24.9
Medium
|
207 out of 928 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Regeneron Pharmaceuticals, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Regeneron Pharmaceuticals, Inc.'s Management of ESG Material Risk is Strong
How do the ESG Risk Ratings work?
Top Material ESG Issues for Regeneron Pharmaceuticals, Inc.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Regeneron Pharmaceuticals, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level